Literature DB >> 33126042

The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study.

W J Koemans1, J C H B M Luijten2, R T van der Kaaij1, C Grootscholten3, P Snaebjornsson4, R H A Verhoeven2, J W van Sandick5.   

Abstract

INTRODUCTION: The Lauren classification of gastric adenocarcinoma describes three histological subtypes, the intestinal, the diffuse and the mixed type carcinoma. The metastatic pattern of gastric adenocarcinoma by histological subtype has not been studied.
METHODS: Gastric adenocarcinoma patients with metastatic disease at the time of diagnosis between 1999 and 2017 were identified through the Netherlands Cancer Registry. The Lauren classification was determined based on pathology reports archived in the Dutch Pathology Registry and was linked to individual cases in the Netherlands Cancer Registry.
RESULTS: Among 8 231 newly diagnosed, metastatic and evaluable gastric adenocarcinoma patients, 57 % had an intestinal type carcinoma, 38 % patients had a diffuse type carcinoma and 5 % had a mixed type carcinoma. Intestinal type carcinomas more often metastasized to the liver (57 % versus 21 %, p < 0.0001) and lungs (13 % versus 7 %, p < 0.0001), whereas diffuse type carcinomas more often metastasized to the peritoneum (58 % versus 29 %, p < 0.0001) and bones (9 % versus 6 %, p < 0.0001). Patients with a diffuse type carcinoma had a worse survival perspective regardless of the number or the location of the metastases.
CONCLUSION: In this national cohort study, metastatic gastric adenocarcinoma of the intestinal type had a predilection for the liver and that of the diffuse type for the peritoneum.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Diffuse type; Gastric cancer; Intestinal type; Lauren classification; Metastatic pattern

Mesh:

Year:  2020        PMID: 33126042     DOI: 10.1016/j.canep.2020.101846

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer.

Authors:  Liang Wang; Wei Li; Yagang Liu; Cui Zhang; Weina Gao; Lifei Gao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  PHLPP1 Overexpression was Associated With a Good Prognosis With Decreased AKT Activity in Gastric Cancer.

Authors:  Sun Yi Park; Sang-Ho Jeong; Eun-Jung Jung; Young-Tae Ju; Chi-Young Jeong; Ju-Yeon Kim; Taejin Park; Jiho Park; Tae-Han Kim; Miyeong Park; Jung Wook Yang; Young-Joon Lee
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

3.  Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.

Authors:  Tiuri E Kroese; Nikita K N Jorritsma; Hanneke W M van Laarhoven; Rob H A Verhoeven; Stella Mook; Nadia Haj Mohammad; Jelle P Ruurda; Peter S N van Rossum; Richard van Hillegersberg
Journal:  Clin Transl Radiat Oncol       Date:  2022-08-24

4.  Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study.

Authors:  Willemieke P M Dijksterhuis; Marianne C Kalff; Anna D Wagner; Rob H A Verhoeven; Valery E P P Lemmens; Martijn G H van Oijen; Suzanne S Gisbertz; Mark I van Berge Henegouwen; Hanneke W M van Laarhoven
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.